A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 760 participants.
Also called NCT07421297
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 760 participants
- Registry
-
NCT07421297
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07421297. Randomized; quadruple masking; primary purpose treatment. Start 2026-02-28 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
- Condition
- Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
- Intervention (Drug)
- SYH2053 injection
- Intervention (Other)
- SYH2053 injection placebo
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Record details
- Record id
cardio:ct-nct07421297- Content hash
c4f861fc902080cb5a7502bb422c9ee4ef5c96f5ad96cb6e140356b7201f3203